IL3 Stoklara Genel Bakış Integra LifeSciences Holdings Corporation, nöroşirürji, nörokritik bakım ve kulak burun boğaz alanlarında kullanılmak üzere cerrahi aletler, nöroşirürji ürünleri ve yara bakım ürünleri üretmekte ve satmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Integra LifeSciences Holdings Corporation Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Integra LifeSciences Holdings Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$25.00 52 Haftanın En Yüksek Seviyesi US$41.60 52 Haftanın En Düşük Seviyesi US$15.30 Beta 1.18 1 Aylık Değişim 11.61% 3 Aylık Değişim 0.81% 1 Yıllık Değişim -34.21% 3 Yıllık Değişim -56.52% 5 Yıllık Değişim -53.27% Halka arzdan bu yana değişim 254.86%
Son Haberler & Güncellemeler
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30 Daha fazla güncelleme görün
Integra LifeSciences Holdings Corporation to Report Q4, 2024 Results on Feb 25, 2025 Feb 04
Integra LifeSciences Launches Integra Institute for Healthcare Professionals (HCPs) Jan 15 Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Updates Earnings Guidance for the Full Year of 2024
Third quarter 2024 earnings released: US$0.14 loss per share (vs US$0.24 profit in 3Q 2023) Nov 04
Investor sentiment deteriorates as stock falls 21% Aug 05
Second quarter 2024 earnings released: US$0.16 loss per share (vs US$0.052 profit in 2Q 2023) Jul 30
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Third Quarter and Updates Earnings Guidance for the Full Year of 2024 Jul 30
Integra LifeSciences Holdings Corporation to Report Q2, 2024 Results on Jul 29, 2024 Jul 16
Integra LifeSciences Holdings Corporation(NasdaqGS:IART) dropped from Russell 1000 Dynamic Index Jul 03
Independent Presiding Director recently bought €917k worth of stock May 23
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2024 May 08
New minor risk - Share price stability May 07
First quarter 2024 earnings released: US$0.042 loss per share (vs US$0.30 profit in 1Q 2023) May 06
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Apr 03 Integra LifeSciences Holdings Corporation to Report Q1, 2024 Results on Apr 25, 2024
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 09, 2024 Mar 27
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases Mar 12
Investor sentiment deteriorates as stock falls 19% Mar 06 Integra LifeSciences Holdings Corporation Announces Board Changes
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024 Feb 29
Full year 2023 earnings released: EPS: US$0.84 (vs US$2.18 in FY 2022) Feb 29
Integra LifeSciences Holdings Corporation to Report Q4, 2023 Results on Feb 28, 2024 Feb 08
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. Dec 14 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million.
Third quarter 2023 earnings released: EPS: US$0.24 (vs US$0.60 in 3Q 2022) Oct 26
Levi & Korsinsky Notifies Integra Lifesciences Holdings Corporation Investors of a Class Action Lawsuit and Upcoming Deadline Oct 20
Integra LifeSciences Holdings Corporation to Report Q3, 2023 Results on Oct 25, 2023 Oct 05
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 14
Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against Integra Lifesciences Holdings Corporation Sep 13
New minor risk - Earnings quality Jul 30 Integra LifeSciences Holdings Corporation (NasdaqGS:IART) announces an Equity Buyback for $225 million worth of its shares.
Second quarter 2023 earnings released: EPS: US$0.052 (vs US$0.54 in 2Q 2022) Jul 27
Integra LifeSciences Holdings Corporation to Report Q2, 2023 Results on Jul 27, 2023 Jul 04 Integra LifeSciences Holding Corporation Announces Complete Enrollment in DuraSorb Monofilament Mesh U.S. IDE Study Jun 29
Integra Lifesciences Holdings Corporation Appoints Lea Daniels Knight as Executive Vice President, Effective June 28, 2023
President recently bought €279k worth of stock Jun 04
Now 35% undervalued after recent price drop May 24
Now 20% undervalued after recent price drop May 03
First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.39 in 1Q 2022) Apr 27
Insider recently sold €95k worth of stock Mar 09
Insider recently sold €203k worth of stock Mar 01
Full year 2022 earnings released: EPS: US$2.16 (vs US$2.00 in FY 2021) Feb 23
Now 20% undervalued Feb 18 Integra LifeSciences Holdings Corporation Announces Executive Changes
Now 21% undervalued Jan 26 Integra LifeSciences Holdings Corporation Provides Revenue Guidance for Fourth Quarter 2022 and Full-Year 2022
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of Surgical Innovation Associates, Inc. Dec 07
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) entered into a definitive agreement to acquire Surgical Innovation Associates, Inc. for $140 million. Dec 02
Third quarter 2022 earnings released: EPS: US$0.60 (vs US$0.51 in 3Q 2021) Oct 27
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year Oct 27
Integra LifeSciences Holdings Corporation to Report Q3, 2022 Results on Oct 26, 2022 Oct 09
Integra LifeSciences Holdings Corporation Appoints Harvinder Singh as Executive Vice President and President of Integra’s International Business Oct 07
Integra LifeSciences Holdings Corporation Announces Resignation of Glenn Coleman as Chief Operating Officer, Effective October 3, 2022 Aug 30
Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO Aug 17
Independent Director recently sold €439k worth of stock Aug 09
An unknown buyer entered into a definitive agreement to acquire Non-core Traditional Wound Care Business of Integra LifeSciences Holdings Corporation (NasdaqGS:IART) for $28.8 million. Jul 29
Second quarter 2022 earnings released: EPS: US$0.54 (vs US$0.41 in 2Q 2021) Jul 28 Integra LifeSciences Holdings Corporation Revises Financial Guidance for the Third Quarter and Full Year 2022
Integra LifeSciences Holdings Corporation Appoints Renee Lo to its Board of Directors Jul 20
Integra LifeSciences Holdings Corporation to Report Q2, 2022 Results on Jul 27, 2022 Jul 02
First quarter 2022 earnings released: EPS: US$0.39 (vs US$0.54 in 1Q 2021) Apr 28
Integra LifeSciences Holdings Corporation, Annual General Meeting, May 13, 2022 Apr 09
Integra LifeSciences Holdings Corporation to Report Q1, 2022 Results on Apr 27, 2022 Apr 02
Insider recently sold €75k worth of stock Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Integra LifeSciences Holdings Corporation Provides Earnings Guidance for the First Quarter and Full Year 2022 Feb 24
Integra LifeSciences Holdings Corporation Provides Revenue Guidance for the Fourth Quarter and Full Year 2021 Jan 12
Insider recently sold €214k worth of stock Nov 09
Third quarter 2021 earnings released: EPS US$0.51 (vs US$0.38 in 3Q 2020) Nov 03
Insider recently sold €242k worth of stock Aug 11
Second quarter 2021 earnings released: EPS US$0.41 (vs US$0.004 loss in 2Q 2020) Jul 29
Integra LifeSciences Announces Positive Clinical Outcomes for Primatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers Jul 20
Independent Director recently sold €69k worth of stock Jun 08
Integra Lifesciences Holdings Corporation Reaffirms Earnings Guidance for Second Quarter and Full Year 2021 May 21
First quarter 2021 earnings released: EPS US$0.53 (vs US$0.11 in 1Q 2020) Apr 30
Integra Lifesciences Holdings Corporation Provides Revenue Guidance for the Second Quarter and Full Year 2021 Apr 29
Independent Director has left the company Mar 01
Insider recently sold €1.4m worth of stock Feb 28
Full year 2020 earnings released: EPS US$1.57 (vs US$0.59 in FY 2019) Feb 20
Revenue beats expectations Feb 20
Integra LifeSciences Holdings Corporation Announces Board Changes, Effective February 26, 2021 Feb 13
Integra LifeSciences Holdings Corporation (NasdaqGS:IART) completed the acquisition of ACell, Inc. Jan 22
Integra LifeSciences Holdings Corporation to Report Q4, 2020 Results on Feb 18, 2021 Jan 15
New 90-day high: €55.00 Jan 14 Hissedar Getirileri IL3 DE Medical Equipment DE Pazar 7D 0.8% -0.2% -0.2% 1Y -34.2% -4.7% 13.7%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: IL3 geçen yıl % -4.7 oranında getiri sağlayan German Medical Equipment sektörünün gerisinde kaldı.
Getiri vs Piyasa: IL3 geçen yıl % 13.7 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is IL3's price volatile compared to industry and market? IL3 volatility IL3 Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: IL3 son 3 ayda German piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: IL3 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Integra LifeSciences Holdings Corporation, nöroşirürji, nörokritik bakım ve kulak burun boğaz alanlarında kullanılmak üzere cerrahi aletler, nöroşirürji ürünleri ve yara bakım ürünleri üretmekte ve satmaktadır. Codman Specialty Surgical ve Tissue Technologies olmak üzere iki segmentte faaliyet göstermektedir. Şirket, doku ablasyon ekipmanı, dural onarım ürünleri, serebral spinal sıvı yönetim cihazları, intrakraniyal izleme ekipmanı ve kraniyal stabilizasyon ekipmanı dahil olmak üzere nöroşirürji ve nöro kritik bakım ürünleri; cerrahi farlar ve enstrümantasyonun yanı sıra pazar sonrası hizmetler sunmaktadır.
Daha fazla göster Integra LifeSciences Holdings Corporation Temel Bilgiler Özeti Integra LifeSciences Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? IL3 temel i̇stati̇sti̇kler Piyasa değeri €1.93b Kazançlar(TTM ) -€6.29m Gelir(TTM ) €1.50b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) IL3 gelir tablosu (TTM ) Gelir US$1.56b Gelir Maliyeti US$632.40m Brüt Kâr US$932.52m Diğer Giderler US$939.06m Kazançlar -US$6.54m
Son Raporlanan Kazançlar
Sep 30, 2024
Sonraki Kazanç Tarihi
Feb 25, 2025
Hisse başına kazanç (EPS) -0.085 Brüt Marj 59.59% Net Kâr Marjı -0.42% Borç/Özkaynak Oranı 118.9%
IL3 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2025/02/05 09:13 Gün Sonu Hisse Fiyatı 2025/02/05 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin .
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github 'da mevcuttur.
Analist Kaynakları Integra LifeSciences Holdings Corporation 30 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum David Toung Argus Research Company Matthew Taylor Barclays Charley Jones Barrington Research Associates, Inc.
Göster 27 daha fazla analist 
